Cipla has reported results for third quarter ended December 31, 2025 (Q3FY26).
The company has reported 57.11% drop in its net profit at Rs 616.88 crore for the third quarter ended December 31, 2025 as compared to Rs 1,438.15 crore for the same quarter in the previous year. The total income of the company decreased by 4.74% at Rs 4,914.78 crore for Q3FY26 as compared Rs 5,159.57 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 56.97% drop in its net profit at Rs 675.80 crore for the third quarter ended December 31, 2025 as compared to Rs 1,570.51 crore for the same quarter in the previous year. The total income of the company decreased by 0.19% at Rs 7,280.82 crore for Q3FY26 as compared Rs 7,294.58 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: